Agenus Inc
AGEN3.500USD
+0.060+1.74%
Market hours （ET）Quotes delayed by 15 min
114.85MMarket Cap
LossP/E TTM
More Details of Agenus Inc Company
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Info
Ticker SymbolAGEN
Company nameAgenus Inc
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Number of employees316
Security typeOrdinary Share
Fiscal year-endFeb 04
Address3 Forbes Rd
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421-7305
Phone17816744400
Websitehttps://agenusbio.com/
Ticker SymbolAGEN
IPO dateFeb 04, 2000
CEOArmen (Garo H)
Company Executives of Agenus Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+205.07%
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
22.08K
+35.46%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
By RegionUSD
Name
Revenue
Proportion
United States
25.16M
97.95%
Rest of World
526.00K
2.05%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Non-cash royalty revenue
24.83M
96.65%
Other services
526.00K
2.05%
Clinical product revenue
334.00K
1.30%
Shareholding Stats
Updated: Sat, Dec 20
Updated: Sat, Dec 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.56%
Invus Public Equities Advisors, LLC
3.13%
B. Riley Financial, Inc
2.23%
Morgan Stanley & Co. LLC
1.45%
BlackRock Institutional Trust Company, N.A.
1.38%
Other
84.26%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.56%
Invus Public Equities Advisors, LLC
3.13%
B. Riley Financial, Inc
2.23%
Morgan Stanley & Co. LLC
1.45%
BlackRock Institutional Trust Company, N.A.
1.38%
Other
84.26%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.38%
Investment Advisor/Hedge Fund
4.70%
Hedge Fund
3.22%
Research Firm
2.98%
Individual Investor
1.70%
Pension Fund
0.36%
Bank and Trust
0.03%
Other
68.64%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
2023Q3
382
11.27M
62.51%
+267.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.53M
7.95%
-16.81K
-0.66%
Jun 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.34%
+564.25K
+112.85%
Jun 30, 2025
B. Riley Financial, Inc
756.96K
2.38%
+756.96K
--
Dec 31, 2024
Morgan Stanley & Co. LLC
719.75K
2.26%
+350.35K
+94.84%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
489.68K
1.54%
-1.12M
-69.54%
Jun 30, 2025
BofA Global Research (US)
420.68K
1.32%
+220.33K
+109.97%
Jun 30, 2025
Armen (Garo H.)
338.69K
1.06%
+7.51K
+2.27%
Sep 19, 2025
Millennium Management LLC
504.51K
1.58%
+504.51K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
317.41K
1%
-226.73K
-41.67%
Jun 30, 2025
Walleye Capital LLC
198.29K
0.62%
+198.29K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Date
Type
Ratio
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Agenus Inc?
The top five shareholders of Agenus Inc are:
The Vanguard Group, Inc. holds 2.53M shares, accounting for 7.95% of the total shares.
Invus Public Equities Advisors, LLC holds 1.06M shares, accounting for 3.34% of the total shares.
B. Riley Financial, Inc holds 756.96K shares, accounting for 2.38% of the total shares.
Morgan Stanley & Co. LLC holds 719.75K shares, accounting for 2.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 489.68K shares, accounting for 1.54% of the total shares.
The Vanguard Group, Inc. holds 2.53M shares, accounting for 7.95% of the total shares.
Invus Public Equities Advisors, LLC holds 1.06M shares, accounting for 3.34% of the total shares.
B. Riley Financial, Inc holds 756.96K shares, accounting for 2.38% of the total shares.
Morgan Stanley & Co. LLC holds 719.75K shares, accounting for 2.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 489.68K shares, accounting for 1.54% of the total shares.
What are the top three shareholder types of Agenus Inc?
The top three shareholder types of Agenus Inc are:
The Vanguard Group, Inc.
Invus Public Equities Advisors, LLC
B. Riley Financial, Inc
The Vanguard Group, Inc.
Invus Public Equities Advisors, LLC
B. Riley Financial, Inc
How many institutions hold shares of Agenus Inc (AGEN)?
As of 2025Q4, 304 institutions hold shares of Agenus Inc, with a combined market value of approximately 9.95M, accounting for 37.38% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.01%.
What is the biggest source of revenue for Agenus Inc?
In FY2025Q2, the Non-cash royalty revenue business generated the highest revenue for Agenus Inc, amounting to 24.83M and accounting for 96.65% of total revenue.
